CVS/caremark

Reference number
1709-H

SPECIALTY QUANTITY LIMIT PROGRAM

SANDOSTATIN (octreotide acetate)
SANDOSTATIN LAR Depot (octreotide acetate for injectable suspension)

I. PROGRAM DESCRIPTION

The initial limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the initial limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Initial Limit*
Sandostatin (octreotide) Inj 100 mcg/mL	Acromegaly: • Recommended starting dose is 50 mcg three times daily. Adjust thereafter based on GH, IGF-1 levels and/or clinical symptoms. • The dose most commonly found to be effective is 100 mcg three times daily, but some patients require up to 500 mcg three times daily, for maximum effectiveness. Carcinoid tumors: • Recommended dose during the first 2 weeks ranges from 100-600 mcg/day in 2-4 divided doses • Daily maintenance dose ranges from 50 mcg/day to 1500 mcg/day. Vasoactive intestinal peptide tumors (VIPomas): • Recommended dose during the first 2 weeks ranges from 200-300 mcg in 2-4 divided doses • Dosage may be adjusted to achieve a therapeutic response • Usually doses above 450 mcg/day are not required	90 per 30 days
Sandostatin (octreotide) Inj 1000 mcg/mL (5 mL multi-dose vials)		9 vials (45,000 units) per 30 days
Sandostatin (octreotide) Inj 200 mcg/mL (5 mL multi-dose vials)		45 vials (45,000 units) per 30 days
Sandostatin (octreotide) Inj 50 mcg/mL		90 per 30 days
Sandostatin (octreotide) Inj 500 mcg/mL		90 per 30 days
Sandostatin (octreotide) Kit LAR 10 mg	Acromegaly: • Recommended starting dose is 20 mg every 4 weeks for 3 months. Adjust thereafter based on GH, IGF-1 levels and/or clinical symptoms. • Doses higher than 40 mg are not recommended Carcinoid tumors and vasoactive intestinal peptide tumors (VIPomas): • 20 mg every 4 weeks for 2 months. Adjust dosage thereafter based on symptoms. Doses higher than 30 mg are not recommended. Renal impairment – patients on dialysis: • 10 mg every 4 weeks Hepatic impairment – patients with cirrhosis: • 10 mg every 4 weeks	10 mg (1 Kit) per 28 days
Sandostatin (octreotide) Kit LAR 20 mg		40 mg (2 Kits) per 28 days
Sandostatin (octreotide) Kit LAR 30 mg		30 mg (1 Kit) per 28 days

*The initial limits may apply to the generic equivalent medications.

III. REFERENCES

1. Sandostatin [package insert]. Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2012.
2. Sandostatin LAR Depot [package insert]. Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2016.